Additionally, the 36-month beta value for KALV is -0.02. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KALV is 38.49M and currently, short sellers hold a 16.16% ratio of that float. The average trading volume of KALV on June 18, 2025 was 615.87K shares.
KALV) stock’s latest price update
The stock price of KalVista Pharmaceuticals Inc (NASDAQ: KALV) has dropped by -6.86 compared to previous close of 13.04. Despite this, the company has seen a fall of -14.53% in its stock price over the last five trading days. businesswire.com reported 2025-06-16 that CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP). Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhi.
KALV’s Market Performance
KALV’s stock has fallen by -14.53% in the past week, with a monthly rise of 1.80% and a quarterly drop of -1.82%. The volatility ratio for the week is 3.33% while the volatility levels for the last 30 days are 3.82% for KalVista Pharmaceuticals Inc The simple moving average for the past 20 days is -4.73% for KALV’s stock, with a 11.03% simple moving average for the past 200 days.
Analysts’ Opinion of KALV
Many brokerage firms have already submitted their reports for KALV stocks, with JMP Securities repeating the rating for KALV by listing it as a “Mkt Outperform.” The predicted price for KALV in the upcoming period, according to JMP Securities is $19 based on the research report published on January 31, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see KALV reach a price target of $30. The rating they have provided for KALV stocks is “Buy” according to the report published on January 07th, 2025.
BofA Securities gave a rating of “Buy” to KALV, setting the target price at $22 in the report published on December 18th of the previous year.
KALV Trading at -2.01% from the 50-Day Moving Average
After a stumble in the market that brought KALV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.65% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALV starting from Palleiko Benjamin L, who sale 7,169 shares at the price of $14.50 back on Jun 09 ’25. After this action, Palleiko Benjamin L now owns 315,074 shares of KalVista Pharmaceuticals Inc, valued at $103,950 using the latest closing price.
Audhya Paul K., the CHIEF MEDICAL OFFICER of KalVista Pharmaceuticals Inc, sale 2,146 shares at $11.31 during a trade that took place back on May 23 ’25, which means that Audhya Paul K. is holding 113,026 shares at $24,272 based on the most recent closing price.
Stock Fundamentals for KALV
Current profitability levels for the company are sitting at:
- -150.43 for the present operating margin
- 0.63 for the gross margin
The net margin for KalVista Pharmaceuticals Inc stands at -145.83. The total capital return value is set at -0.72. Equity return is now at value -150.50, with -90.20 for asset returns.
Based on KalVista Pharmaceuticals Inc (KALV), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -22.08. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -63.84.
Currently, EBITDA for the company is -134.28 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of 366.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.44.
Conclusion
In conclusion, KalVista Pharmaceuticals Inc (KALV) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
